05/15/13, Research and Development Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer more
04/10/13, Research and Development Bayer HealthCare to broaden strategic alliance with German Cancer Research Center Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year more
|Research expenses 2012||EUR 1,556 million|
|In percent of division sales 2012
|Employees in Research & Development||7,500
(as of Dec 31, 2012)
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.